Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30460332 | 0.81 | ALDH1A1 (0.39) | ALDH1A1HPGDKDM4EALPLADORA3 | |
| SCHEMBL20997723 | 0.79 | ALDH1A1 (0.35) | ALDH1A1HPGDKDM4EALPLUSP2 | |
| SCHEMBL30657797 | 0.78 | MAPT (0.31) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL28484688 | 0.75 | ALPL (0.33) | ALDH1A1HPGDKDM4EALPLADORA3 | |
| SCHEMBL30657791 | 0.74 | ALDH1A1 (0.35) | ALDH1A1HPGDKDM4EALPLADORA3 | |
| SCHEMBL13906517 | 0.73 | USP2 (0.44) | ALDH1A1HPGDKDM4EUSP2LMNA | |
| SCHEMBL20668745 | 0.72 | ALDH1A1 (0.42) | ALDH1A1HPGDKDM4EALPLADORA3 | |
| SCHEMBL16019755 | 0.70 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4EALPLADORA3 | |
| SCHEMBL16019754 | 0.69 | ALDH1A1 (0.45) | ALDH1A1HPGDKDM4EALPLADORA3 | |
| SCHEMBL595428 | 0.69 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4EALPLADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-111978327-B | Preparation method of ticagrelor | 南京一心和医药科技有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-111978328-B | Synthesis method of ticagrelor | 南京一心和医药科技有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-9604991-B2 | Preparation method of ticagrelor and intermediates thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-28 | — | — | US | disclosed |
| US-9604991-B2 | Preparation method of ticagrelor and intermediates thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-28 | — | — | US | disclosed |
| US-20160102101-A1 | Preparation method of Ticagrelor and intermediates thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2016-04-14 | — | — | US | disclosed |
| US-20160102101-A1 | Preparation method of Ticagrelor and intermediates thereof | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2016-04-14 | — | — | US | disclosed |
| WO-2014102830-A1 | A PROCESS FOR PREPARATION OF TICAGRELOR AND INTERMEDIATES THEREOF | MEGAFINE PHARMA (P) LTD. (IN) | 2014-07-03 | — | — | WO | disclosed |
| WO-2012138981-A2 | NEW INTERMEDIATES AND PROCESSES FOR PREPARING TICAGRELOR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-10-11 | — | — | WO | disclosed |
| EP-1232172-A1 | NOVEL RIBOSE COMPOUNDS | AstraZeneca AB (SE) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001036438-A1 | NOVEL RIBOSE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102101-A1 | Preparation method of Ticagrelor and intermediates thereof | TPMT, NUDT1, ITPA | ALDH1A1 640/4885HPGD 639/4885KDM4E 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.